We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+38.53%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$524M
AUM Growth
+$84.8M
(+19%)
Cap. Flow
-$21.1M
Cap. Flow
% of AUM
-4.01%
Top 10 Holdings %
Top 10 Hldgs %
56.21%
Holding
96
New
14
Increased
18
Reduced
28
Closed
8
Avg Time Held
11.6
quarters
Top 10 Avg Time Held
9.5
quarters
Top 20 Avg Time Held
11.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$11.2M |
| 2 |
Denali Therapeutics
DNLI
|
+$8.64M |
| 3 |
Insulet
PODD
|
+$8.5M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$5.91M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$3.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Day One Biopharmaceuticals
DAWN
|
+$21M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$16.5M |
| 3 |
Biohaven
BHVN
|
+$7.62M |
| 4 |
MBX Biosciences
MBX
|
+$5.72M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$5.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.52% |
| 2 | Miscellaneous | 7.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$40.4B
| $105M | 20.09% |
562,630
-18,048
| -3% | -$2.64M |
2020 Q4
22 quarters
|
|
|
2
State Street SPDR S&P Biotech ETF
XBI
$9.71B
| $31.1M | 5.93% |
196,505
-122,000
| -38% | -$16.5M |
2022 Q1
17 quarters
|
|
3
Compass Pathways
CMPS
$1.54B
| $28.5M | 5.43% |
2,011,952
-406,930
| -17% | -$4.13M |
2023 Q3
11 quarters
|
|
4
Stereotaxis
STXS
$106M
| $23.5M | 4.49% |
13,680,554
| – | – |
2013 Q2
52 quarters
|
|
|
5
Nektar Therapeutics
NKTR
$1.3B
| $22.2M | 4.24% |
318,380
+153,202
| +93% | +$11.2M |
2025 Q2
4 quarters
|
|
|
6
Denali Therapeutics
DNLI
$2.94B
| $19M | 3.62% |
739,014
+420,514
| +132% | +$8.64M |
2025 Q1
5 quarters
|
|
7
IDEAYA Biosciences
IDYA
$3.31B
| $18.5M | 3.53% |
497,240
+20,500
| +4% | +$628K |
2020 Q3
23 quarters
|
|
8
AtriCure
ATRC
$2.9B
| $16.7M | 3.19% |
597,431
| – | – |
2013 Q2
52 quarters
|
|
9
Xenon Pharmaceuticals
XENE
$3.34B
| $15.1M | 2.89% |
250,772
| – | – |
2015 Q3
43 quarters
|
|
10
Cytokinetics
CYTK
$8.57B
| $14.7M | 2.79% |
171,998
-45,499
| -21% | -$3.27M |
2021 Q3
19 quarters
|
|
11
Arcus Biosciences
RCUS
$2.87B
| $13.6M | 2.6% |
441,829
-2,000
| -0.5% | -$49.4K |
2020 Q1
25 quarters
|
|
|
12
Ascendis Pharma A/S
ASND
$14.7B
| $12.9M | 2.47% |
48,469
+25,292
| +109% | +$5.91M |
2021 Q4
18 quarters
|
|
13
Neurocrine Biosciences
NBIX
$13.7B
| $9.74M | 1.86% |
57,769
-12,846
| -18% | -$1.91M |
2016 Q1
41 quarters
|
|
14
Axogen
AXGN
$2.12B
| $9.65M | 1.84% |
208,960
-41,000
| -16% | -$1.65M |
2021 Q4
18 quarters
|
|
|
15
Insulet
PODD
$9.58B
| $9.42M | 1.8% |
61,870
+51,000
| +469% | +$8.5M |
2024 Q1
9 quarters
|
|
|
16
Edgewise Therapeutics
EWTX
$3.94B
| $9.22M | 1.76% |
226,819
+114,583
| +102% | +$3.95M |
2022 Q1
17 quarters
|
|
17
Bicara Therapeutics
BCAX
$1.15B
| $8.46M | 1.61% |
284,955
-136,778
| -32% | -$3.05M |
2024 Q4
6 quarters
|
|
18
iShares Biotechnology ETF
IBB
$10.2B
| $8.1M | 1.55% |
42,595
-19,500
| -31% | -$3.35M |
2016 Q4
38 quarters
|
|
19
Syndax Pharmaceuticals
SNDX
$1.25B
| $7.33M | 1.4% |
335,255
+117,900
| +54% | +$2.45M |
2020 Q2
24 quarters
|
|
20
MapLight Therapeutics
MPLT
$438M
| $6.13M | 1.17% |
171,006
| – | – |
2025 Q4
2 quarters
|
|
21
Larimar Therapeutics
LRMR
$222M
| $6.12M | 1.17% |
2,008,164
-21,000
| -1% | -$83.4K |
2018 Q2
32 quarters
|
|
22
Century Therapeutics
IPSC
$250M
| $5.88M | 1.12% |
2,400,458
-33,895
| -1% | -$77.4K |
2021 Q2
20 quarters
|
|
23
DexCom
DXCM
$32.1B
| $5.81M | 1.11% |
86,279
| – | – |
2017 Q3
35 quarters
|
|
24
Immunovant
IMVT
$5.93B
| $5.76M | 1.1% |
149,524
-1,000
| -0.7% | -$30.5K |
2023 Q3
11 quarters
|
|
25
Inogen
INGN
$168M
| $5.45M | 1.04% |
845,179
| – | – |
2019 Q1
29 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, DAFNA Capital Management held 96 positions worth $524M, up 19% from $440M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
DAFNA Capital Management withdrew a net $21.1M in Q2 2026, closing 8 positions and reducing 28 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in NervGen Pharma worth $2.16M.
- DAFNA Capital Management's largest Q2 2026 buy was NervGen Pharma: 1,050,000 shares worth $2.16M.
- DAFNA Capital Management added most to Nektar Therapeutics in Q2 2026, an estimated $11.2M increase.
- DAFNA Capital Management's biggest Q2 2026 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $16.5M.
- DAFNA Capital Management fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $21M.
- DAFNA Capital Management's ten largest holdings make up 56% of its $524M portfolio in Q2 2026.
- DAFNA Capital Management opened 14 new positions and closed 8 in Q2 2026.
- DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $524M.
Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.